Human LILRA3/CD85e Protein

Cat. No. LIL-HM4A3

Description

Source	Recombinant Human LILRA3/CD85e Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.
	It contains Gly24-Glu439.
Accession	Q8N6C8
Molecular Weight	The protein has a predicted MW of 47.9 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Human LILRA3, also known as Leukocyte Ig-like receptor 4 (LIR-4), CD85 antigen-like family member E, Immunogobulin-like transcript 6 (ILT-6) and monocyte inhibitory receptor HM43/HM31, is a 70 kD Ig superfamily member that belongs to the leukocyte receptor complex/cluster. Mature LILRA3 is 416 amino acids (aa) in length and contains four C2-type Ig-like domains. Unlike other LILR family members, LILRA3 is actively secreted.LILRA3 acts as soluble receptor for class I MHC antigens. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes.

Assay Data

Bis-Tris PAGE



Human LILRA3 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.